(PRWEB) January 9, 2005
BioCardia, Inc. and Symphony Medical, Inc. announce a mutually exclusive agreement for development and commercialization of a combination product that combines Symphony Medical's biotherapeutic technology and BioCardia device delivery technology for the treatment of cardiac conduction disorders. Symphony Medical will have distribution rights to the combination product.
Peter Altman, CEO of BioCardia states: "Symphony is developing a strategy that has promise to provide enormous benefit to patients worldwide. We are honored to be able to work together on this cutting edge product strategy that has potential to help millions of patients. Our collaboration creates value for both BioCardia and Symphony Medical shareholders and there are synergies between us on many levels."
Mark Maciejewski, CEO of Symphony Medical states: "We are confident that the technology, experience, and intellectual property of BioCardia maximize our probability of technical and commercial success. This relationship will be good for both organizations as well as the patients whose lives we aim to improve together."
BioCardia, Inc. has developed one of the leading integrated catheter drug delivery platforms designed to enable safe and routine delivery of biotherapeutics to solid organs. BioCardia develops and markets catheter systems for device and biological delivery and is actively partnering with leading biotherapeutic companies for local delivery to the heart.
Symphony Medical, Inc. develops novel biopolymer and cellular therapies for the treatment of cardiac conduction disorders.
For more information please visit http://www.biocardia.com.
Contact: Investor Relations, BioCardia, Inc. 650-624-0900, Miranda Peto
# # #